The Hippo pathway and human cancer

By K. Harvey, Xiaomeng Zhang, David M. Thomas. Nature Reviews. Cancer, 2013

1,781 citations recorded by the source corpus.

Subfields: Cell Biology, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/cac7577e8872fad124c06f0404c6d660ece4a233

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cell Biology

In Molecular Biology

In Oncology

Citations in the corpus

YAP/TAZ at the roots of cancer (2016, background): “Yet, this assumption contrasts with the reality that Hippo pathway mutations are extremely rare in human tumors (Harvey et al., 2013).”
The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment (2013, neutral): “Importantly, while specific defects that deregulate the Hippo pathway in many cancers are not known, the core components are largely unaffected by irreversible mutations or genetic aberrations 7 .”
Network-based machine learning and graph theory algorithms for precision oncology (2017, background): “97, 109 Finally, the PI3K-Akt pathway has been identi ﬁ ed as one of the most frequently affected pathways in several cancer types, and several components of this pathway were reported to be mutated or ampli ﬁ ed in various cancer types.”
The Hippo pathway effectors TAZ and YAP in development, homeostasis and disease (2014, background): “It is noteworthy that TAZ and/or YAP localization and levels are dysregulated in a broad range of cancers, which I have not covered in depth here (for a recent review see Harvey et al., 2013).”
Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth (2015, methodology): “Following these results, we performed a ChIP-seq experiment for endogenous TEAD4 and found that 78% (5,522) of YAP/TAZ peaks overlapped with TEAD4 peaks (Fig.”
The biology of YAP/TAZ: hippo signaling and beyond. (2014, background): “Indeed, with the exception of inherited disorders associated with NF2, somatic mutations in the core Hippo members are extremely rare in human tumors (82).”
Metabolic control of YAP and TAZ by the mevalonate pathway (2014, background): “YAP is amplified in several human cancers through mechanisms that remain still unknown (Harvey et al., 2013).”
Signal transduction in cancer. (2015, neutral): “…a critical role in regulating contact inhibition of proliferation (Harvey and Hariharan 2012), and disruption of this pathway, which suppresses the transcriptional coactivator YAP, is emerging as a key tumor suppressor pathway in many cancers (Harvey et al. 2013; Lin et al. 2013; Yu andGuan 2013).”
A mechanical checkpoint controls multicellular growth through YAP/TAZ regulation by actin-processing factors. (2013, neutral): “A number of human cancers hijack these properties to foster their own growth, including induction of cancer stem cells and metastatic colonization (Cordenonsi et al., 2011; Harvey et al., 2013).”
Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer (2014, neutral): “Yap1, a transcriptional coactivator and the downstreammediator of Hippo signaling, is regulated posttranscriptionally by either kinase-mediated degradation or cytoplasmic sequestration (Harvey et al., 2013; Zhao et al., 2011).”
The Hippo signalling pathway and its implications in human health and diseases (2022, background): “Because the Hippo pathway is an essential survival-associated signalling pathway, inactivation of this pathway could increase cell proliferation and decrease apoptosis, contributing to tumour initiation and progression.(3,219) Tumour initiation and progression require metabolic reprogramming.”